Tenax Therapeutics Inc TENX Fundamentals and Key Ratios

Tenax Therapeutics Inc. (TENX) Fundamentals


Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com.

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com.

SHARE INFORMATION
Market Cap	$ 5,559,059
Shares Outstanding	9,265,099
Float	9,180,465
Percent Float	99.09%
Short Interest	0.00
Short Percent Float	0.0%
Short Interest Ratio	0.00
Short Interest Date	-
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 0
Latest Fiscal EPS	$ -38.60
Latest Fiscal Date	2021-12-31

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	39
Institutional Holdings Date	2023-02-28
Institutional Bought Previous 3 Months	79,412
Institutional Holdings Percent	2.9%
Institutional Sold Previous 3 Months	395,079
Insider Holdings Date	2023-02-28
Insider Bought Previous 3 Months	-
Insider Holdings Percent	61.2
Insider Sold Previous 3 Months	-
Insider Shares Owned	5,666,720

TRADING INFO
52 Week High	$ 17.00
52 Week Low	$ 0.45
52 Week High Change	$ -95.29
21 Day Moving Average	$ 0.6197
21 Day Extended Moving Average	$ 0.71143
50 Day Moving Average	$ 1.3229
50 Day Extended Moving Average	$ 1.194
200 Day Moving Average	$ 3.8265
200 Day Extended Moving Average	$ 4.9011
10 Day Average Volume	14,009,100
20 Day Average Volume	9,228,372
30 Day Average Volume	6,519,235
50 Day Average Volume	4,850,934
Alpha	-0.051335
Beta	2.1527
Standard Deviation	0.300472
R2	0.148847
7 Day Price Change	$ 0.031
7 Day Percent Change	5.45%
21 Day Price Change	$ -0.0476
21 Day Percent Change	-7.35%
30 Day Price Change	$ -0.1041
30 Day Percent Change	-14.78%
Month to Date Price Change	$ -0.08
Month to Date Percent Change	-11.76%
Quarter to Date Price Change	$ -1.63
Quarter to Date Percent Change	-73.07%
180 Day Price Change	$ -3.26
180 Day Percent Change	-84.46%
200 Day Price Change	$ -3.53
200 Day Percent Change	-85.47%
Year to Date Price Change	$ -1.63
Year to Date Percent Change	-73.07%

PROFITABILITY
EBIT Margin	0.0%
EBITDA Margin	0.0%
Pre-Tax Profit Margin	0.0%
Profit Margin Count	0.0%
Gross Margin	0.0%
Profit Margin TOT	0.0%

INCOME STATEMENTS
Revenue	$ 0
Revenue Per Share	$ 0.00
Revenue (3 Years)	$ 0.00
Revenue (5 Years)	$ 0.00

FINANCIAL STRENGTH
Price to Tangible Book	1.50
Total Debt To Equity	0.10
Int Coverage	-2,634.50
Current Ratio	6.50
Leverage Ratio	1.40
Quick Ratio	5.50
Long Term Debt To Capital	0.02

VALUATION MEASURES
PE Ratio	-0.10
Enterprise Value	$ 2,279,263
Price to Sales	0.00
Price to Free Cash	-0.60
PE High Last 5 Years	-0.30
Price To Book	1.50
Price To Cash Flow	0.00
PE Low Last 5 Years	-0.70
Price to Tangible Book	1.50

MANAGEMENT EFFECTIVENESS
Receivables Turnover	0.00
Invoice Turnover	0.00
Assets Turnover	0.00
Return Assets	-190.58
Return on Equity	-232.20
Return on Capital	-199.75

PROFILE INFO
Issue Type	CS
SEC Type	EQS
Auditor	Cherry Bekaert LLP
CEO	Anthony A. DiTonno
Emplyoees	10
Last Audit	UE
CIK	0000034956
Industry	Biotechnology
Sector	Healthcare
NAICS	Research and Development in Biotechnology (except Nanobiotechnology)(541714)

CONTACT INFO
Address	ONE Copley Parkway Suite 490 Morrisville, NC 27560
Website	http://www.tenaxthera.com
Facsimile	+1 919 855-2133
Telephone	+1 919 855-2100
Email	jesse@sternir.com

Boards:

Quotes:

TENX